The company’s shares increased by 0.8 percent following the announcement. Recently, Johnson & Johnson’s stock took a dive.
“Based on our continued strong performance and, more importantly, the confidence we have in our business going forward, the board of directors and management team believe that the company’s shares are an attractive investment opportunity,” Alex Gorsky, Johnson & Johnson CEO, said in a statement, according to the report.
With the repurchase plan, Johnson & Johnson does not expect to take on any debt. The company also reaffirmed its 2018 sales and earnings guidance.
More articles on devices and implants:
Pediatric orthopedic company signs licensing agreement for guided growth plates: 3 notes
Zimmer Biomet celebrates 10 years in Ireland
Mizuho OSI celebrates 40 years
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.